“It could be that the integration of a new treatment modality into the bladder-sparing arena is a tipping point that is needed to really have the community embrace this as a reasonable option for patients with bladder cancer,” says Matthew Galsky, MD.
Mark Christopher Markowski, MD, PhD, discusses phase 1b/2 data for the novel oral cytoskeletal disruptor VERU-111 in metastatic castration-resistant prostate cancer being presented during the 2021 ASCO Annual Meeting.
Robert J. Motzer, MD, discusses how the outcomes of the phase 3 CLEAR trial impact the use of pembrolizumab/lenvatinib in patients with renal cell carcinoma.
Neeraj Agarwal, MD, discusses health-related quality of life and patient-reported outcomes from the phase 3 TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.
Smruthy Sivakumar, PhD, discusses results from a large-scale analysis of ancestry, patterns of gene alterations, comprehensive genomic profiling, and treatment patterns in nearly 12,000 patients with prostate cancer.
Viktor Grünwald, MD, discusses a subanalysis of the phase 3 CLEAR trial.
Agarwal also discusses the ongoing phase 3 randomized CONTACT-02 study.
“We had a very low rate of nonattendance amongst oncology appointments, as compared to some other appointments,” says Randie White, MD.
Andre Abreu, MD, and Phillip Kuo, MD, PhD, on future use of PSMA targeted therapy, including insight on the phase 3 VISION trial, which used 68Ga-PSMA-11 PET/CT to identify patients for targeted treatment with 177Lu-PSMA-617.
The FDA’s approval of Ga-68 PSMA-11 and its impact on ensuring accessibility of generator versus cyclotron for new radiotracers is discussed from a nuclear medicine perspective.
“There is a lot of debate about the final shape and form of what telemedicine should look like,” says Chad Ellimoottil, MD, MS, in this video.
In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.
In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.
In Urology Times’ monthly installment of Around the Practice, experts discuss adverse event management from various treatments for prostate and bladder cancer.
Jason Zhu, MD, discusses how next-generation imaging is critical to advancing personalized medicine in prostate cancer.
In this video, Jennifer M. Taylor, MD, MPH, also shares one of her strategies to cope with burnout and provides advice for others struggling with burnout.
Phillip Kuo, MD, PhD, reviews the sensitivity of PSMA (prostate-specific membrane antigen) PET (positron emission tomography) scans compared to conventional imaging.
Andre Abreu, MD, discusses the rationale behind targeting PSMA (prostate-specific membrane antigen) and its impact on the patient journey from diagnosis to biochemical recurrence.
Ranjith Ramasamy, MD, explains how the oral testosterone capsule Jatenzo works and touches on key findings from a recent study of the treatment.
“I think doctors should be aware that if men do complain of erectile dysfunction after [having] COVID-19 that it could be because of underlying endothelial dysfunction and underlying vasculature issues,” Ramasamy says.
Looking back at the November 2020 installment of Urology Times’ Around the Practice, a virtual, monthly live case event focused on genitourinary cancers, Raoul S. Concepcion, MD, FACS, offers an update on clinical implications from two prostate cancer cases.
The history and resultant benefits of PET (positron emission tomography) along with the utilization of PSMA (prostate-specific membrane antigen) PET imaging in treating prostate cancer is discussed.
Andre Abreu, MD, and Phillip Kuo, MD, PhD, define the standard of care and the limitations in prostate cancer imaging.
“We found that there is going to be a significant proportion of growth in the urology work force related to the number of women in urology, which is really exciting,” says Kate H. Kraft, MD.
The PARP inhibitors olaparib and rucaparib are approved by the FDA for prostate cancer and other PARP agents are moving through the pipeline.
Ellimoottil also discusses the status of his own practice with regards to in-person vs telemedicine visits.
“Speak out. speak out. If you're a physician who's going through a hard time, I can promise you you're not alone,” says Raj S. Pruthi, MD, MHA, FACS.
“I really fell in love with [urology] from the get go,” Kraft says.
“In this study, we show that AI can be used to speed up the time-consuming step of outlining the prostate that's required for targeted prostate biopsy,” says Geoffrey Sonn, MD.
The risk assessment tool helps determine whether a prostate biopsy is necessary when PSA screening is ambiguous.
